RT Journal
A1 Psaty BM
T1 COnflict of interest, disclosure, and trial reports
JF JAMA
JO JAMA
YR 2009
FD April 8
VO 301
IS 14
SP 1477
OP 1479
DO 10.1001/jama.2009.466
UL http://dx.doi.org/10.1001/jama.2009.466
AB 
When I was an assistant professor, my previous training had not prepared me for the unexpected attention that 2 articles, both from the same study, were to receive. One article provided evidence that abruptly stopping β-blockers might increase the risk of coronary events.1 The other suggested that, compared with the use of high-dose diuretics, which is now no longer recommended, the use of β-blockers might be associated with a lower risk of coronary events in hypertensive patients.2 While the news media's coverage of the risk study was transient, the pharmaceutical industry had a more sustained interest in the other publication.